Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
生物技術日報:安進、吉利德去購物,爲處於早期乳腺癌的阿斯利康的Lynparza點頭,阿爾茨海默氏相關幻覺候選人的決策日
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer
The European Union has approved AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc's (NYSE:MRK) Lynparza (olaparib) for human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
The approval for Lynparza comes as monotherapy or in combination with endocrine therapy for the adjuvant treatment in the breast cancer setting with germline BRCA1/2 mutations.
Syros Bone Marrow Cancer Candidate Poised To Get...
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要:
Stocks In Focus
焦點股票
AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer
阿斯利康/默克的Lynparza在早期乳腺癌方面獲得歐洲的認可
The European Union has approved AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc's (NYSE:MRK) Lynparza (olaparib) for human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
歐盟已批准阿斯利康有限公司(納斯達克股票代碼:AZN)和默克公司的(NYSE: MRK) Lynparza(olaparib)用於先前接受過新輔助或輔助化療治療的人表皮生長因子受體2(HER2)陰性的高危早期乳腺癌。
The approval for Lynparza comes as monotherapy or in combination with endocrine therapy for the adjuvant treatment in the breast cancer setting with germline BRCA1/2 mutations.
Lynparza的批准是單一療法或與內分泌療法聯合使用,用於具有種系BRCA1/2突變的乳腺癌環境中的輔助治療。
Syros Bone Marrow Cancer Candidate Poised To Get...
賽羅斯骨髓癌候選...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!